Literature DB >> 12945021

Topical amitriptyline in healthy volunteers.

Peter Gerner1, Grace Kao, Venkatesh Srinivasa, Sanjeet Narang, Ging Kuo Wang.   

Abstract

BACKGROUND AND OBJECTIVES: The antidepressant amitriptyline is used as an adjuvant in the treatment of a variety of chronic pain conditions. This drug interacts with many receptors and ion channels, such as Na+ channels. In a randomized, double-blinded, and placebo-controlled trial, we investigated whether amitriptyline also is capable of providing cutaneous analgesia when applied topically in 14 healthy volunteers.
METHODS: Amitriptyline hydrochloride was prepared as a 45% water/45% isopropanol/10% glycerin solution and titrated to pH 8.5 with sodium hydroxide. Four areas, 2 on each arm, of approximately 1 cm(2) each were marked on the ventral aspect of the upper arm. A piece of gauze, placed on each of the marked areas and affixed to the arm with an occlusive plastic dressing, was saturated via syringe with placebo and amitriptyline solutions (10 mmol/L, 50 mmol/L, and 100 mmol/L). After 1 hour, the dressings and gauze were removed. A 16-G blunt needle was used to grade the pain at the marked area once per hour (1 = complete analgesia, 10 = normal pain sensation).
RESULTS: The analgesic effects of 50 mmol/L and 100 mmol/L solutions of amitriptyline were significantly higher than those of the placebo or the 10 mmol/L solution. However, no significant difference was found between the analgesia provided by the placebo solution versus the 10 mmol/L solution or between the 50 mmol/L versus the 100 mmol/L solution. The only side effect observed was a concentration-dependent redness of the skin.
CONCLUSIONS: Topically applied amitriptyline is effective as an analgesic in humans. Different vehicles may improve its efficacy and decrease the skin redness observed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12945021     DOI: 10.1016/s1098-7339(03)00209-8

Source DB:  PubMed          Journal:  Reg Anesth Pain Med        ISSN: 1098-7339            Impact factor:   6.288


  11 in total

Review 1.  Targeted peripheral analgesics therapy for neuropathic pain.

Authors:  Charles E Argoff
Journal:  Curr Pain Headache Rep       Date:  2004-06

Review 2.  Topical treatments for pain.

Authors:  Charles E Argoff
Journal:  Curr Pain Headache Rep       Date:  2004-08

3.  Antidepressants inhibit Nav1.3, Nav1.7, and Nav1.8 neuronal voltage-gated sodium channels more potently than Nav1.2 and Nav1.6 channels expressed in Xenopus oocytes.

Authors:  Takafumi Horishita; Nobuyuki Yanagihara; Susumu Ueno; Dan Okura; Reiko Horishita; Tomoko Minami; Yuichi Ogata; Yuka Sudo; Yasuhito Uezono; Takeyoshi Sata; Takashi Kawasaki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-09-14       Impact factor: 3.000

4.  A greater role for the norepinephrine transporter than the serotonin transporter in murine nociception.

Authors:  F S Hall; J M Schwarzbaum; M T G Perona; J S Templin; M G Caron; K-P Lesch; D L Murphy; G R Uhl
Journal:  Neuroscience       Date:  2010-12-01       Impact factor: 3.590

Review 5.  Topical agents for the treatment of chronic pain.

Authors:  Charles E Argoff
Journal:  Curr Pain Headache Rep       Date:  2006-02

Review 6.  Localized neuropathic pain: an expert consensus on local treatments.

Authors:  Gisèle Pickering; Elodie Martin; Florence Tiberghien; Claire Delorme; Gérard Mick
Journal:  Drug Des Devel Ther       Date:  2017-09-13       Impact factor: 4.162

Review 7.  Topical Treatments and Their Molecular/Cellular Mechanisms in Patients with Peripheral Neuropathic Pain-Narrative Review.

Authors:  Magdalena Kocot-Kępska; Renata Zajączkowska; Joanna Mika; David J Kopsky; Jerzy Wordliczek; Jan Dobrogowski; Anna Przeklasa-Muszyńska
Journal:  Pharmaceutics       Date:  2021-03-26       Impact factor: 6.321

8.  Genetic variation in the serotonin transporter gene (5-HTTLPR, rs25531) influences the analgesic response to the short acting opioid Remifentanil in humans.

Authors:  Eva Kosek; Karin B Jensen; Tina B Lonsdorf; Martin Schalling; Martin Ingvar
Journal:  Mol Pain       Date:  2009-07-01       Impact factor: 3.395

9.  Central neuropathic pain in a patient with multiple sclerosis treated successfully with topical amitriptyline.

Authors:  David J Kopsky; Remko Liebregts; Jan M Keppel Hesselink
Journal:  Case Rep Med       Date:  2012-07-18

10.  Amitriptyline 2% cream vs. capsaicin 0.75% cream in the treatment of painful diabetic neuropathy (Double blind, randomized clinical trial of efficacy and safety).

Authors:  Javad Kiani; Saman Ahmad Nasrollahi; Farzaneh Esna-Ashari; Puyan Fallah; Firuzeh Sajedi
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.